Although TRK inhibitors such as larotrectinib and entrectinib have demonstrated efficacy in treating NTRK fusion-positive CRC, the mechanisms underlying disease progression—including the development of PTTM—remain poorly understood. Here, NTRK1 is linked to colorectal carcinoma.